Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of “Moderate Buy” by Brokerages

Exelixis, Inc. (NASDAQ:EXEL) has received a consensus rating of “Moderate Buy” from the fifteen analysts that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $27.67.

A number of analysts recently issued reports on the company. JMP Securities reissued a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a research report on Friday, September 20th. Royal Bank of Canada reissued an “outperform” rating and issued a $27.00 price objective on shares of Exelixis in a report on Thursday, September 26th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Exelixis in a report on Wednesday, September 18th. Oppenheimer reiterated an “outperform” rating and issued a $29.00 price target on shares of Exelixis in a research report on Tuesday, July 30th. Finally, Truist Financial reissued a “buy” rating and set a $33.00 price objective (up from $32.00) on shares of Exelixis in a research report on Thursday, August 8th.

Insider Buying and Selling

In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of the firm’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the transaction, the chief financial officer now directly owns 721,680 shares in the company, valued at approximately $19,622,479.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the transaction, the chief financial officer now owns 721,680 shares of the company’s stock, valued at $19,622,479.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Dana Aftab sold 95,000 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total value of $2,375,000.00. Following the completion of the sale, the executive vice president now owns 520,990 shares in the company, valued at $13,024,750. The disclosure for this sale can be found here. Insiders have sold 327,858 shares of company stock worth $8,640,129 in the last three months. Corporate insiders own 2.85% of the company’s stock.

Hedge Funds Weigh In On Exelixis

Institutional investors and hedge funds have recently modified their holdings of the company. Sanctuary Advisors LLC acquired a new stake in shares of Exelixis during the second quarter worth $652,000. Creative Planning boosted its stake in Exelixis by 0.8% in the 2nd quarter. Creative Planning now owns 71,700 shares of the biotechnology company’s stock worth $1,611,000 after buying an additional 548 shares during the last quarter. Algert Global LLC grew its holdings in Exelixis by 7.6% in the 2nd quarter. Algert Global LLC now owns 276,352 shares of the biotechnology company’s stock valued at $6,210,000 after buying an additional 19,559 shares during the period. Mackenzie Financial Corp increased its stake in shares of Exelixis by 62.1% during the 2nd quarter. Mackenzie Financial Corp now owns 433,311 shares of the biotechnology company’s stock valued at $9,736,000 after acquiring an additional 166,057 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its holdings in shares of Exelixis by 137.1% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 20,816 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 12,036 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Trading Down 1.0 %

Shares of NASDAQ:EXEL opened at $26.24 on Friday. The firm has a 50 day simple moving average of $25.79 and a 200-day simple moving average of $23.55. Exelixis has a twelve month low of $18.64 and a twelve month high of $27.83. The company has a market capitalization of $7.96 billion, a PE ratio of 41.00, a P/E/G ratio of 0.56 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The firm had revenue of $637.18 million during the quarter, compared to analysts’ expectations of $468.21 million. As a group, equities research analysts predict that Exelixis will post 1.59 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.